Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk

Background: Chronic inflammation is an important mechanism for the development and progression of prostate cancer (PC). To better understand the potential relationship between genes in the inflammation pathway and PC risk, we evaluated variants in 16 candidate genes. Methods: A total of 143 tagging and amino acid altering single nucleotide polymorphisms (SNPs) were genotyped in Caucasian and African American men participating in one of two population-based, case–control studies (n = 1,458 cases and 1,351 controls). The relative risk of PC was estimated using logistic and polytomous regression models. Results: Ten SNPs in seven genes (CXCL12, IL4, IL6, IL6ST, PTGS2, STAT3, and TNF) were nominally associated (P < 0.05) with risk of PC in Caucasians. The most significant effect on risk was seen with rs11574783 in the interleukin 6 signal transducer (IL6ST) gene (OR = 0.08, 95% CI: 0.01–0.63). Cumulatively, four SNPs in genes interleukin 4 (IL4), IL6ST, PTGS2, and signal transducer and activator of transcription 3 (STAT3) conferred a three-fold elevation in PC risk among men carrying the maximum number of high-risk alleles (OR = 2.97, 95% CI: 1.41–6.25, Ptrend = 0.0003). Risk estimates for seven SNPs varied significantly according to disease aggressiveness (Phomogeneity < 0.05), with SNPs in AKT1, PIK3R1, and STAT3 independently associated with more aggressive PC; OR = 5.1 (95% CI: 2.29–11.40, Ptrend = 3.8 × 10−5) for carriers of all high-risk genotypes. Conclusions: These results suggest that variants in genes within the inflammation pathway may play a role in the development of PC, however, further studies are needed to replicate our findings. Impact: These results underline the potential importance of the inflammation pathway in PC development and progression. Cancer Epidemiol Biomarkers Prev; 20(5); 923–33. ©2011 AACR.

[1]  Bingshu E. Chen,et al.  Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies. , 2007, Carcinogenesis.

[2]  T. Wheeler,et al.  The emerging role of the PI3-K-Akt pathway in prostate cancer progression , 2005, Prostate Cancer and Prostatic Diseases.

[3]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[4]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[5]  J. Stanford,et al.  Genetic etiology of hereditary prostate cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[6]  D. Bostwick,et al.  Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. , 2007, The Journal of urology.

[7]  P. Abel,et al.  Cytoplasmic induction and over‐expression of cyclooxygenase‐2 in human prostate cancer: implications for prevention and treatment , 2000, BJU international.

[8]  K. Lange,et al.  Prioritizing GWAS results: A review of statistical methods and recommendations for their application. , 2010, American journal of human genetics.

[9]  P. Nelson,et al.  American Journal of Epidemiology Original Contribution Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk Caucasian and African-american Men 35–74 Years of Age Residing in King County, Washington, Who Were Diagnosed , 2022 .

[10]  S. Shapiro,et al.  Vasectomy and the risk of prostate cancer. , 1990, American journal of epidemiology.

[11]  Eugene S. Edgington,et al.  Randomization Tests , 2011, International Encyclopedia of Statistical Science.

[12]  L. Dennis,et al.  Epidemiologic association between prostatitis and prostate cancer. , 2002, Urology.

[13]  R. Hayes,et al.  Sexually Transmissible Infections and Prostate Cancer Risk , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  H. Mukhtar,et al.  Cyclooxygenase-2 and prostate carcinogenesis. , 2003, Cancer letters.

[15]  A. Gao,et al.  Interleukin‐4 stimulates androgen‐independent growth in LNCaP human prostate cancer cells , 2008, The Prostate.

[16]  Michael F. Lin,et al.  Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals , 2009, Nature.

[17]  C. Pan,et al.  Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. , 2001, Anticancer research.

[18]  H. Grönberg,et al.  Genetic variability in inflammation pathways and prostate cancer risk. , 2007, Urologic oncology.

[19]  M. Thun,et al.  PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). , 2010, Carcinogenesis.

[20]  G. Wise,et al.  Cytokine variations in patients with hormone treated prostate cancer. , 2000, The Journal of urology.

[21]  A. Sabichi,et al.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. , 2001, Cancer research.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  H. Grönberg,et al.  Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. , 2005, Journal of the National Cancer Institute.

[24]  R. Grobholz,et al.  Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer , 2003, International journal of cancer.

[25]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[26]  R. Houlston,et al.  A systematic review and meta‐analysis of familial prostate cancer risk , 2003, BJU international.

[27]  W. Isaacs,et al.  Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II , 2009, The Prostate.

[28]  M. Murai,et al.  Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. , 2005, Urology.

[29]  J. Karras,et al.  Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. , 2004, Molecular cancer therapeutics.

[30]  T. Heinemeyer,et al.  Databases on transcriptional regulation : TRANSFAC , TRRD and COMPEL , 1997 .

[31]  W Li,et al.  Marker Selection by Akaike Information Criterion and Bayesian Information Criterion , 2001, Genetic epidemiology.

[32]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[33]  J. Witte,et al.  COX2 genetic variation, NSAIDs, and advanced prostate cancer risk , 2007, British Journal of Cancer.

[34]  H. Grönberg,et al.  Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX‐2 polymorphism , 2007, International journal of cancer.

[35]  Stampfer,et al.  PTGS 2 and IL 6 genetic variation and risk of breast and prostate cancer : results from the Breast and Prostate Cancer Cohort Consortium ( BPC 3 ) , 2010 .

[36]  A. Badawi.  The role of prostaglandin synthesis in prostate cancer , 2000, BJU international.

[37]  E. Hurt,et al.  The role of IL-6 and STAT3 in inflammation and cancer. , 2005, European journal of cancer.

[38]  R. Dhir.  Stat3 Promotes Metastatic Progression of Prostate Cancer , 2009 .

[39]  R. Eeles,et al.  Influence of cytokine gene polymorphisms on the development of prostate cancer. , 2002, Cancer research.

[40]  H. Mohrenweiser,et al.  Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1) , 2007, Pharmacogenetics and genomics.

[41]  J. Beebe-Dimmer,et al.  Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia , 2006, CA: a cancer journal for clinicians.

[42]  R. Kittles,et al.  Delivery technique plays an important role in determining vessel wall apposition of the Enterprise self-expanding intracranial stent , 2011, Journal of Neurointerventional Surgery.

[43]  W. Reichelt,et al.  Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols , 2004, Molecular Cancer.

[44]  J. Stanford,et al.  Statin use and risk of prostate cancer: results from a population-based epidemiologic study. , 2008, American journal of epidemiology.

[45]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[46]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[47]  Mark I. McCarthy,et al.  A Genome-Wide Association Study Identifies Protein Quantitative Trait Loci (pQTLs) , 2008, PLoS genetics.

[48]  H. Grönberg,et al.  Genetic variation in the COX‐2 gene and the association with prostate cancer risk , 2006, International Journal of Cancer.

[49]  Peter Kraft,et al.  Pooled analysis of phosphatidylinositol 3-kinase pathway variants and risk of prostate cancer. , 2010, Cancer research.